Loading
Blood clots are the second commonest cause of death in people with cancer. Risk scores identify who should take preventive blood thinners during chemotherapy, and direct oral anticoagulants have largely replaced injections for treatment.
Cancer raises venous thromboembolism risk 4-7-fold (highest in pancreatic, gastric, brain, lung cancers and myeloma on IMiDs). The Khorana score (2008) identifies high-risk outpatients; AVERT (apixaban) and CASSINI (rivaroxaban) trials (2019) showed primary thromboprophylaxis roughly halves VTE in Khorana ≥2 patients with acceptable bleeding, now recommended by ASCO/ITAC/NCCN. Treatment: LMWH was standard after CLOT (2003); Hokusai VTE Cancer (edoxaban), SELECT-D (rivaroxaban), Caravaggio (apixaban) established DOACs, with LMWH preferred for luminal GI tumours (bleeding) and drug interactions. Duration ≥6 months while cancer active. Central venous catheter thrombosis, arterial events with VEGF inhibitors and BTK inhibitors, and incidental PE are common management problems. Anticoagulation in brain tumours and thrombocytopenia requires individualisation.
Stratify VTE risk (tumour type, chemotherapy, biomarkers) to target prophylaxis; treat established thrombosis with anticoagulation weighed against tumour-specific bleeding risk.
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Query for this technology: (TITLE:"Cancer-associated thrombosis prevention and treatment" OR ABSTRACT:"Cancer-associated thrombosis prevention and treatment") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cancer-associated thrombosis prevention and treatment, not a curated reading list.
Shares Palliation in pancreatic cancer: biliary and duodenal stents, coeliac plexus block, enzymes and cachexia, Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag supportive.
Shares Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag supportive.
Shares Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag supportive.
Shares Palliation in pancreatic cancer: biliary and duodenal stents, coeliac plexus block, enzymes and cachexia, Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Glioma & glioblastoma, Pancreatic ductal adenocarcinoma and the tag supportive.
Shares Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards and the tag supportive.
Shares Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag supportive.
Shares Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Cytotoxic chemotherapy and the tag supportive.
Shares Multiple myeloma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag supportive.